Alkermes (ALKS) EBT Margin Growth (3y) (2013 - 2026)
Alkermes (ALKS) EBT Margin Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 1,282.00 |
| 3 | Zoetis | 31.79 Bn | 30.11 Bn | 1.05 Bn | -491.00 |
| 4 | Takeda Pharmaceutical | 28.69 Bn | 22.89 Bn | 5.10 Bn | 58.00 |
| 5 | United Therapeutics | 22.25 Bn | 19.58 Bn | 683.80 Mn | -861.00 |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -1,020.00 |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | -995.00 |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 1,157.00 |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Alkermes | 8.15 Bn | 7.49 Bn | 397.90 Mn | -4,603.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4,603.00 |
| Mar 31, 2026 | -1,182.00 |
| Dec 31, 2025 | -2,188.00 |
| Sep 30, 2025 | 213,081.00 |
| Jun 30, 2025 | 106,590.00 |
| Mar 31, 2025 | 2,447.00 |
| Dec 31, 2024 | 29.00 |
| Sep 30, 2024 | 3,817.00 |
| Jun 30, 2024 | 2,738.00 |
| Mar 31, 2024 | 2,081.00 |
| Dec 31, 2023 | 3,032.00 |
| Sep 30, 2023 | 2,351.00 |
| Jun 30, 2023 | 5,605.00 |
| Mar 31, 2023 | 878.00 |
| Dec 31, 2022 | 8,872.00 |
| Sep 30, 2022 | -208,415.00 |
| Jun 30, 2022 | -102,463.00 |
| Mar 31, 2022 | 2,878.00 |
| Dec 31, 2021 | 4,272.00 |
| Sep 30, 2021 | 458.00 |